

Paul C Langley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6746238/publications.pdf>

Version: 2024-02-01

41
papers

701
citations

687220

13
h-index

552653

26
g-index

41
all docs

41
docs citations

41
times ranked

591
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of pain on labor force participation, absenteeism and presenteeism in the European Union. <i>Journal of Medical Economics</i> , 2010, 13, 662-672.	1.0	104
2	The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization. <i>Journal of Medical Economics</i> , 2010, 13, 571-581.	1.0	97
3	The prevalence, correlates and treatment of pain in Spain. <i>Journal of Medical Economics</i> , 2011, 14, 367-380.	1.0	79
4	The November 1995 Revised Australian Guidelines for the Economic Evaluation of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1996, 9, 341-352.	1.7	38
5	Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 1185-1190.	0.5	37
6	Disease Management Programs. <i>American Journal of Health-System Pharmacy</i> , 1996, 53, 53-58.	0.5	33
7	Validation of modeled pharmacoeconomic claims in formulary submissions. <i>Journal of Medical Economics</i> , 2015, 18, 993-999.	1.0	33
8	The societal burden of pain in Germany: Health-related quality-of-life, health status and direct medical costs. <i>Journal of Medical Economics</i> , 2012, 15, 1201-1215.	1.0	30
9	The impact of rheumatoid arthritis on the burden of disease in urban China. <i>Journal of Medical Economics</i> , 2011, 14, 709-719.	1.0	28
10	A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts. <i>Journal of Medical Economics</i> , 2010, 13, 1-7.	1.0	20
11	The association of pain with labor force participation, absenteeism, and presenteeism in Spain. <i>Journal of Medical Economics</i> , 2011, 14, 835-845.	1.0	18
12	Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada. <i>Pharmacoeconomics</i> , 1999, 16, 211-224.	1.7	17
13	Measurement, modeling and QALYs. <i>F1000Research</i> , 2020, 9, 1048.	0.8	16
14	Nonsense on Stilts “ Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds. <i>Innovations in Pharmacy</i> , 2020, 11, 12.	0.2	14
15	The Great I-QALY Disaster. <i>Innovations in Pharmacy</i> , 2020, 11, 7.	0.2	13
16	Na domhain shamhlaÃochta: formulary submission guidelines in Ireland and the standards of normal science. <i>Current Medical Research and Opinion</i> , 2016, 32, 1641-1644.	0.9	11
17	Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure. <i>Innovations in Pharmacy</i> , 2021, 12, 6.	0.2	11
18	Nullius in verba: The University of Minnesota Social and Administrative Pharmacy Program proposed Guidelines for Formulary Evaluations. <i>Innovations in Pharmacy</i> , 2016, 7, .	0.2	10

#	ARTICLE	IF	CITATIONS
19	Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?. Current Medical Research and Opinion, 2004, 20, 181-188.	0.9	9
20	Peripheral Vascular Disorders. Pharmacoeconomics, 1997, 11, 225-236.	1.7	8
21	The status of modeled claims. Journal of Medical Economics, 2015, 18, 991-992.	1.0	8
22	Cost Effectiveness and the Allocation of Therapies in a Treating Population. Pharmacoeconomics, 1996, 10, 93-98.	1.7	7
23	Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment. Innovations in Pharmacy, 2021, 12, 20.	0.2	7
24	Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 689-695.	0.5	6
25	Fundamental Outcome Measurement: Selecting Patient Reported Outcome Instruments and Interpreting the Data they Produce. Innovations in Pharmacy, 2021, 12, 17.	0.2	6
26	Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines. Innovations in Pharmacy, 2020, 11, 12.	0.2	6
27	Time since diagnosis, treatment pathways and current pain status: a retrospective assessment in a back pain population. Journal of Medical Economics, 2013, 16, 701-709.	1.0	5
28	Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience. Innovations in Pharmacy, 2021, 12, 5.	0.2	5
29	Fundamental Measurement and Quality-Adjusted Life Years. Value in Health, 2021, 24, 461.	0.1	5
30	Nothing to Cheer About: Endorsing an Imaginary Economic Evaluations and Value Claims with CHEERS 22. F1000Research, 2022, 11, 248.	0.8	5
31	Treatment of Pneumonias in a Managed-Care Organisation. Disease Management and Health Outcomes, 1999, 6, 159-173.	0.3	4
32	Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines. Innovations in Pharmacy, 2020, 11, .	0.2	4
33	Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims. Innovations in Pharmacy, 2021, 12, 11.	0.2	2
34	A Practice Based Behavioral Health Management Registry (BHMR): Implementation, Structure and Content. Innovations in Pharmacy, 2019, 10, 3.	0.2	2
35	Tracking and Reporting Outcomes in Medical Marijuana: Establishing Condition Specific State Level Registries. Innovations in Pharmacy, 2019, 10, 4.	0.2	1
36	Value Assessment in Cystic Fibrosis: ICER's Rejection of the Axioms of Fundamental Measurement. Innovations in Pharmacy, 2020, 11, 8.	0.2	1

#	ARTICLE	IF	CITATIONS
37	To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims. <i>Innovations in Pharmacy</i> , 2020, 11, 22.	0.2	1
38	Cost Effectiveness and Allocation of Therapies in a Treating Population: The Author's Reply. <i>Pharmacoeconomics</i> , 1997, 11, 606-608.	1.7	0
39	The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 119.	0.6	0
40	The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). <i>Innovations in Pharmacy</i> , 2020, 11, .	0.2	0
41	The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). <i>Innovations in Pharmacy</i> , 2020, 11, 17.	0.2	0